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tetrahydropyrimidine‑5‑carboxylic 
acid analogs as betaine/GABA  
transporter 1 (BGT1) substrate‑ 
inhibitors
Stefanie Kickinger1, Anas Al‑Khawaja2, Anne Stæhr Haugaard2, Maria E. K. Lie2, 
francesco Bavo2, Rebekka Löffler2, Maria Damgaard2, Gerhard F. Ecker 1*, 
Bente frølund2* & petrine Wellendorph2*
We have previously identified 2‑amino‑1,4,5,6‑tetrahydropyrimidine‑5‑carboxylic acid (ATPCA) as 
the most potent substrate‑inhibitor of the betaine/GABA transporter 1 (BGT1)  (IC50 2.5 µM) reported 
to date. Herein, we characterize the binding mode of 20 novel analogs and propose the molecular 
determinants driving BGT1‑selectivity. A series of N1‑, exocyclic‑N‑, and C4‑substituted analogs 
was synthesized and pharmacologically characterized in radioligand‑based uptake assays at the 
four human GABA transporters (hGATs) recombinantly expressed in mammalian cells. Overall, the 
analogs retained subtype‑selectivity for hBGT1, though with lower inhibitory activities (mid to 
high micromolar  ic50 values) compared to ATPCA. Further characterization of five of these BGT1‑
active analogs in a fluorescence‑based FMP assay revealed that the compounds are substrates 
for hBGT1, suggesting they interact with the orthosteric site of the transporter. In silico‑guided 
mutagenesis experiments showed that the non‑conserved residues Q299 and E52 in hBGT1 as well 
as the conformational flexibility of the compounds potentially contribute to the subtype‑selectivity 
of ATPCA and its analogs. Overall, this study provides new insights into the molecular interactions 
governing the subtype‑selectivity of BGT1 substrate‑inhibitors. The findings may guide the rational 
design of BGT1‑selective pharmacological tool compounds for future drug discovery.
γ-Aminobutyric acid (GABA) (Fig. 1) is the principal inhibitory neurotransmitter in the central nervous system 
and plays a fundamental role in the overall balance between neuronal excitation and  inhibition1,2. Dysfunc-
tional GABAergic neurotransmission is implicated in a number of neurological disorders, including  epilepsy3, 
 insomnia4, and  stroke5–7. As members of the GABAergic system, the four GABA transporters (GATs) play a 
critical role in the regulation and termination of the GABA-mediated signaling. They function as key proteins in 
neurotransmitter  uptake8. GATs belong to the solute carrier 6 (SLC6) transporter family and comprise four sub-
types, GAT1, BGT1 (betaine/GABA transporter 1), GAT2, and  GAT39. GAT1 is the most abundantly expressed 
subtype in the mammalian brain and is primarily located in  neurons10, whereas GAT3 is primarily located in 
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 astrocytes10,11. While only scarcely expressed in the brain, GAT2 and BGT1 are abundantly expressed in the liver 
and the kidneys where they mediate the uptake of osmoprotectants such as taurine and betaine,  respectively10,12,13. 
In the brain, Schousboe et al.14 proposed BGT1 to play a specific role at extrasynaptic sites, and BGT1 inhibitors 
have been found to be anticonvulsant.
Pharmacological inhibition of GATs leads to extracellular GABA accumulation, which results in an increased 
inhibitory GABAergic neurotransmission mediated by the activation of GABA  receptors15–17. This renders GATs 
attractive targets in the treatment of GABA-implicated disorders, and various inhibitors have been  developed18–22. 
The GAT1-selective inhibitor, tiagabine (Gabitril) (Fig. 1), was approved by the FDA in the 1990s for the treat-
ment of partial epileptic  seizures23. Due to the high expression level of GAT1 and its divergent sequence identity 
compared to the other GAT subtypes, the majority of developed inhibitors has been designed to target this 
 subtype20,24. However, substantial side effects linked to GAT1 inhibition, such as asthenia, dizziness, nervous-
ness, and  depression25–27, have limited the use of tiagabine, and interest in the non-GAT1 subtypes, especially 
BGT1, has therefore  emerged18,19,28.
The GAT1/BGT1 selective inhibitor, EF1502 (N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-4-(methylamino)-
4,5,6,7-tetrahydro-benzo[d]isoxazol-3-ol)29 and the selective BGT1 inhibitor, RPC-425 (6-((4,4-bis(3-methyl-
thiophen-2-yl)but-3-en-1-yl)(methyl)amino)cyclohex-1-ene-1-carboxylic acid)30, (Fig. 1) exhibit anticonvul-
sive effects in animal models, which are proposed to be BGT1-mediated6,30–33. Recently, the conformationally 
restricted GABA analog, (1S,2S,5R-5-aminobicyclo[3.1.0]hexane-2-carboxylic acid (1), has been reported as 
the first highly selective competitive BGT1 inhibitor with submicromolar potency  (IC50 590 nM)34. However, its 
mode of inhibition and its anticonvulsive potential remain elusive. Given the reported anticonvulsive effect of 
Figure 1.  Structures of γ-aminobutyric acid (GABA); the highly selective GAT1 inhibitor, tiagabine; the mixed 
BGT1/GAT1 inhibitor, EF1502; the moderately selective BGT1 inhibitor, RPC-425; the moderately selective 
BGT1 substrate-inhibitors, ATPCA and 2; nipecotic acid, and general structures of the synthesized compounds.
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several BGT1 inhibitors, the supposed extrasynaptic location of  BGT16,14, and abundant liver and kidney expres-
sion, further clarification of the potential role of BGT1 as a drug target is needed. This is even more important 
given the contradictory findings that BGT1-knockout mice do neither show altered seizure susceptibility nor 
intolerance to salt  treatment13,35.
The development of highly selective non-GAT1 inhibitors has been hampered by the high sequence identity 
of BGT1, GAT2 and  GAT336,37. Nevertheless, we have previously succeeded in developing a series of cyclic 
2-amino-tetrahydropyrimidine/pyridine compounds by utilizing the GAT1-selective substrate, nipecotic acid 
(Fig. 1), as a template. These compounds were identified as substrate-inhibitors with pronounced selectivity 
towards BGT1 over the other  GATs38. Within the series, 2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic 
acid (ATPCA) and the corresponding amidine analog (6-amino-2,3,4,5-tetrahydropyridine-3-carboxylic acid, 
2 (Fig. 1) displayed the highest potencies towards BGT1  (IC50 2.5 µM and 9.8 µM, respectively)38. However, the 
molecular determinants for the observed BGT1-selectivity remain elusive.
In this study, we evaluate the structure–activity relationship (SAR) of a new series of ATPCA analogs and 
examine their mechanism of uptake inhibition. Furthermore, to explore the molecular interactions governing 
BGT1-selectivity, we perform mutational studies guided by computational docking and molecular dynamics 
simulations.
Results and discussion
Chemistry. A series of ATPCA analogs (Fig. 1) was synthesized to elucidate the SAR of subtype-selective 
hBGT1 inhibition. The structural design relied upon systematically investigating the effect of substituents in 
the 2-amino-tetrahydropyrimidine scaffold and conformationally constraining the pharmacophoric elements. 
Inspired by previous reports demonstrating that the introduction of bulky lipophilic substituents at the amino 
group of small GABA uptake inhibitors increases  potency20, we synthesized a series of N1 and exocylic-N substi-
tuted analogs of ATPCA, as outlined in Fig. 2.
The series of N1-alkylated analogs (3–9) was synthesized from commercially available ethyl 2-aminopy-
rimidine-5-carboxylate 20 (Fig. 2a). Acetyl protection of the guanidino primary amine afforded 21, which was 
hydrogenated using catalytic Pd/C. The resulting tetrahydropyrimidine intermediate 22 was alkylated using 
either cesium carbonate and an appropriate alkyl bromide, yielding the N1-alkylated compounds 23–2739, or 
with lithium carbonate and 4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl methanesulphonate, providing 28, 
which carries the same N-substituent as  EF150229. Deprotection afforded the target compounds 3–8. To probe 
the influence of conformational rigidity in N1/N3-alkylated compounds, intermediate 21 was also reduced to the 
almost flat dihydropyrimidine 29, followed by N-benzylation and deprotection to provide the target compound 9.
To avoid polyalkylation, the 2-amino alkylated analog 10 was achieved by a coupling between the commer-
cially available ethyl 2-chloropyrimidine-5-carboxylate 31 and 2-phenylethan-1-amine to give 32 (Fig. 2a)40. 
Catalytic hydrogenation (33), followed by hydrolysis under acidic conditions, afforded the target compound 10.
To probe the impact of conformational flexibility of the tetrahydropyrimidine scaffold on BGT1 activity, the 
dihydropyrimidine analogs of ATPCA 11–14 were pursued. Selective reduction of the 2-aminopyrimidines 34–37 
was achieved in excellent yields when applying triethylsilane and trifluoroacetic acid (Fig. 2b), as reported by 
Baskaran et al.41. No trace of the fully reduced tetrahydropyrimidine was detected, probably due to conjugative 
stabilization of the 2-amino-dihydropyrimidine by the 5-carboxylic acid.
The corresponding tetrahydropyrimidines 15–17 were pursued by catalytic hydrogenation of the 2-aminopy-
rimidine-5-carboxylic acids (35–37) using Pd/C (Fig. 2b). However, all attempts to obtain the target 4-substituted 
2-amino-tetrahydropyrimidine-5-carboxylic acid analogs resulted in rapid decarboxylation. Therefore, catalytic 
hydrogenation, using Pd/C starting from the commercially available pyrimidine esters 38–40, was performed, 
followed by acidic hydrolysis. Only the cis isomers were detected as products in the hydrogenation step.
Based on initial pharmacological characterization of the 4-methyl substituted 2-amino-tetrahydro-pyrimidine 
analog 15 (Table 1), we decided to investigate the impact of stereochemistry on the observed BGT1 activity and 
selectivity. To avoid acidic hydrolysis following enantiomeric separation of 15, we used the carboxylic acid 35 as 
the starting compound, carefully monitoring the hydrogenation reaction. Catalytic hydrogenation of 35, using 
Pd/C in 28 h, afforded a mixture of cis (70%), trans (10%), and decarboxylated product (20%), based on 1H-NMR 
(data not shown). The four isomers were separated on a ChirobioticT preparative column (25 cm × 21.2 mm, 
5 µm), using a flow of 5 ml/min and EtOH/H2O  (NH4OAc 20 mM, pH 4) (30:70, v/v) as a mobile phase (Fig. 2b). 
The enantiomeric purity was > 95%. Unfortunately, the absolute configuration of these two pairs of enantiomers 
could not be determined. Our attempt to crystallize the single stereoisomers in order to determine the absolute 
configuration through X-Ray crystallography was not successful. We therefore refer to the enantiomeric pairs 
as l-15 and u-15 (i.e. (R*R*)-15 and (R*S*)-15, respectively) indicating the relative stereochemistry and to the 
single stereoisomers as l-15a, l-15b, u-15a and u-15b.
An alternative approach had to be taken for the synthesis of the aromatic substituted analogs 18 and 19, 
which were obtained via a condensation reaction between the commercially available ethyl 2-amino-4-meth-
ylpyrimidine-5-carboxylate (38) and the benzaldehyde or biphenyl-4-carbaldehyde, respectively, yielding the 
intermediates 41 and 42. Catalytic hydrogenation using Pd/C afforded the 4-substituted tetrahydropyrimidine 
analogs, where the cis isomers were formed as the major products. Thus, only the cis-stereoisomers were isolated 
and subjected to acidic hydrolysis, yielding the target compounds l-18 and l-19 (Fig. 2b).
Pharmacology. The synthesized ATPCA analogs (Fig. 1) were evaluated in  [3H]GABA uptake assays at the 
four human GATs (hGATs) stably expressed in Chinese hamster ovary (CHO) Flp-In cells (Table 1). All com-
pounds, except for 4, showing inhibitory activity at hBGT1 (tested in concentrations from 0.1 µM to 1 mM), 
displayed selectivity for this subtype. Introduction of an ethyl, a benzyl, or even a 4-biphenylmethyl group in the 
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Figure 2.  (a) Synthesis of the N1-alkylated target compounds 3–9 and of the exocyclic N-alkylated target 
compound 10. Reagents and conditions: (a)  Ac2O, reflux (21); (b) 2-phenylethan-1-amine, TEA, 2-propanol, 
100 °C (32); (c)  H2, Pd/C, EtOH, AcOH (22, 33); (d)  Cs2CO3, KI,  R2-Br, DMF (23–27, 30) or  Li2CO3, AcOiPr, 
 R2-OMs, reflux, 12 h (28); (e) HCl (4 M), 80 °C (3–7, 10); (f) NaOH (0.5 M), 90 °C, 6 h (8, 9); (g) TFA,  Et3SiH 
(29). (b) Synthesis of the C4-substituted target compounds 11–19. Reagents and conditions: (a) TFA,  Et3SiH, 
DCM (11–14); (b)  H2, Pd/C, MeOH, AcOH; (c) HCl (4 M), 80 °C (15–19); (d) preparative chiral HPLC (l-15a,b 
and u-15a,b). (e) Aromatic aldehyde, glacial acetic acid, 130 °C (41, 42).
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N1 position (3, 4, and 5) was tolerated, but decreased the inhibitory potencies 20–65 times compared to ATPCA. 
Interestingly, 4 was equipotent at all subtypes except hGAT1, whereas 5 showed at least 7 times increased selec-
tivity towards hBGT1compared to 4. Since we were not able to generate full inhibition curves for 3, 11, l-15a,b, 
and u-15a,b at hGAT1-3, we can only estimate their hBGT1 selectivity. Based on the less than 50% inhibition 
at the highest concentration tested (1,000 µM), the analogs 3, 11 l-15a, and u-15b showed at least 12, 21, 29, 
and 12 times increased subtype-selectivity for hBGT1, respectively. For l-15b and u-15a, however, the selectiv-
ity was only around 2–3 times more pronounced for hBGT1. In contrast to previously reported structurally 
related GABA uptake  inhibitors42, increasing the carbon chain length and changing the position of the distal 
phenyl group led to a loss of inhibitory activity at any of the hGATs as shown for 6 and 7, respectively. Likewise, 
the introduction of a phenylethyl substituent in the exocyclic-N position (10) was detrimental to the inhibitory 
activity. The dihydropyrimidine analog 11, representing a conformationally less flexible core scaffold of ATPCA, 
showed 19-fold reduced inhibitory activity to that of the parent compound ATPCA. However, introduction of 
alkyl substituents, such as methyl (12), n-propyl (13), and iso-propyl (14), led to a complete loss of activity. The 
same tendency was observed for the corresponding 4-n-propyl and 4-iso-propyl tetrahydropyrimidine analogs 
Table 1.  [3H]GABA uptake inhibitory activities of ATPCA and analogs at recombinant hGATs. Structures 
are depicted in Fig. 1. The compounds were tested for their ability to inhibit the uptake of 30 nM  [3H]GABA 
for 3 min at recombinant hGATs stably expressed in CHO Flp-In cells. The experiments were performed 
in triplicates in at least three independent experiments (compounds marked with * were only tested in 
two independent experiments). N.D., not determined. All compounds are racemic mixtures unless stated 
otherwise. Concentration response curves for selected compounds can be found in the Supplementary 
Figs. S21 and S22. a Adapted from Al-Khawaja et al.38. b The concentration-inhibition curves of these 
compounds were fitted to the value of 100% uptake inhibition in the presence of GABA (3 mM). c These 
compounds displayed less than 50%  [3H]GABA uptake inhibition at the highest tested concentration of 
1,000 µM. d These compounds were tested in tsA201 cells transiently expressing hBGT1.
IC50  (pIC50 ± S.E.M.) (µM)
R1 R2 hBGT1 hGAT1 hGAT2 hGAT3
ATPCA – – 2.5(5.60 ± 0.11)a  > 1,000
c 41
(4.39 ± 0.09)a
99
(4.00 ± 0.03)a
2 – – 13(4.89 ± 0.02)
216
(3.67 ± 0.01)  > 1,000
c  > 1,000c
3 Ethyl H 86(4.07 ± 0.02)b  > 1,000
c  > 1,000c  > 1,000c
4 Benzyl H 163(3.79 ± 0.03)b  > 1,000
c 105
(3.98 ± 0.04)b
117
(3.93 ± 0.005)b
5 4-Biphenylmethyl H 50(4.30 ± 0.03)
1,044
(2.98 ± 0.03)b
382
(3.42 ± 0.05)b
396
(3.42 ± 0.10)b
6* 3,3-Diphenylpropyl H  > 1,000c  > 1,000c  > 1,000c  > 1,000c
7* 4,4-Diphenylbutyl H  > 1,000c  > 1,000c  > 1,000c  > 1,000c
8 4,4-bis(3-Methyl-2-thienyl)3-butenyl H 621
d
(3.21 ± 0.03)d N.D N.D N.D
9 –  > 1,000 N.D N.D N.D
10 H Phenylethyl  > 1,000c 439(3.37 ± 0.07)  > 1,000
c  > 1,000c
11 H – 48(4.33 ± 0.08)  > 1,000
c  > 1,000c  > 1,000c
12 Methyl –  > 1,000c  > 1,000c  > 1,000c  > 1,000c
13 N-propyl –  > 1,000c  > 1,000c 530(3.30 ± 0.10)b  > 1,000
c
14 i-Propyl –  > 1,000c  > 1,000c 1,010(3.02 ± 0.10)b  > 1,000
c
l-15 Methyl – 42(4.38 ± 0.03) N.D N.D N.D
l-15a Methyl – 34(4.47 ± 0.06)  > 1,000
c  > 1,000c  > 1,000c
l-15b Methyl – 442(3.38 ± 0.09)b  > 1,000
c  > 1,000c  > 1,000c
u-15a Methyl – 292(3.57 ± 0.12)b  > 1,000
c  > 1,000c  > 1,000c
u-15b Methyl – 85(4.11 ± 0.11)  > 1,000
c  > 1,000c  > 1,000c
16 N-Propyl –  > 1,000c  > 1,000c 601(3.23 ± 0.05)  > 1,000
c
17 i-Propyl –  > 1,000c  > 1,000c  > 1,000c  > 1,000c
l-18 phenylethyl –  > 1,000c  > 1,000c  > 1,000c  > 1,000c
l-19 4-biphenylethyl –  > 1,000c  > 1,000c  > 1,000c  > 1,000c
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16 and 17, respectively. Larger aromatic substituents, such as phenylethyl (l-18) and 4-biphenylethyl (l-19), led 
to a similar loss of inhibitory activity. In contrast, the 4-methyl analog 15 showed activity at hBGT1. Investiga-
tion of the four stereoisomers, l-15a,b and u-15a,b revealed in each of the two l and u enantiomeric pairs a trend 
for stereoselective inhibitory activity. However, this was more pronounced for l-15a,b, showing a 13-fold differ-
ence in inhibitory activity, compared to the respective trans isomers u-15a,b.
We have previously demonstrated that ATPCA is a substrate for hBGT1, using the fluorescence-based FLIPR 
Membrane Potential (FMP)  assay38,43. To examine whether derivatization of ATPCA converted some of the 
analogs into non-transportable inhibitors of hBGT1, we tested 2, 3, 5, 11, and l-15a in the FMP assay. These 
compounds showed  IC50 values below 100 µM in the  [3H]GABA uptake assay at hBGT1 (Table 1). In the FMP 
assay, the compounds showed a concentration-dependent increase in the fluorescence signal at hBGT1 stably 
expressed in CHO Flp-In cells, suggesting that they are all substrates for hBGT1 and that derivatization did not 
convert the analogs into non-transportable inhibitors. Since all tested compounds are GABA analogs it is very 
likely that they interact with the orthosteric pocket of the transporter (Fig. 3).
Identification of the molecular determinants for BGT1‑selectivity. To delineate the molecular 
determinants for the observed BGT1-selectivity, computational docking studies and molecular dynamics (MD) 
simulations, followed by mutagenesis experiments, were performed. Selected compounds (ATPCA, 2–5, 11–14, 
l-15a,b, and u-15a,b) were docked into the orthosteric binding site of an already published outward-occluded 
homology model of  hBGT144 applying an induced fit docking  protocol45. This substrate specific transporter con-
formation was chosen because ATPCA and the analogs 2, 3, 5, 11, and l-15a displayed substrate characteristics 
in the FMP assay. Docking into homology models of hGAT2 or hGAT3 was not performed since all compounds, 
except for ATPCA and 4 and 5, showed no activity at these transporters. The docking was performed at pH 7.4 
which led to the zwitterionic form of all compounds (see methods section). The poses were analyzed according 
to an in-house protocol for common-scaffold  clustering46–48. Briefly, the docking poses were assembled into 33 
clusters (Supplementary Fig. S1), where the most populated cluster contained poses of all active compounds 
except for 4 and 5 (Supplementary Fig.  S2). Since all compounds share the scaffold of either ATPCA or 11 
(Fig. 1), a single top-scored pose of this cluster, based on the Glide Emodel  score49, for either of the two com-
pounds was selected for subsequent refinement using MD simulations. The poses were simulated three times for 
20 ns to investigate the stability of the protein–ligand interactions.
The MD results of the selected ATPCA pose showed stable hydrogen bonding between ATPCA’s guanidine 
moiety and the side chains of Q299 and E52 (Fig. 4a,c and Supplementary Fig. S3). Q299 constitutes a unique 
residue in hBGT1, corresponding to L300/L294/L314 in hGAT1/hGAT2/hGAT3, whereas E52 only differs in 
hGAT1, corresponding to  Y6037,50,51. Interestingly, the corresponding residues in both positions were already 
identified by others to play a role in substrate specificity in homologous  transporters52,53. The N3 nitrogen of 
ATPCA’s guanidine moiety forms a π-cationic interaction with the highly conserved F293, which is part of the 
extracellular lid of  hBGT137. ATPCA’s carboxyl group coordinates the sodium ion (Na1) and undergoes hydrogen 
bonding with G57, which is conserved among the GATs, as well as with the sidechain of Y133, which is also a 
highly conserved residue since it is part of the extracellular  lid37,50,54. The docking and MD results of 11 showed a 
similar interaction pattern to that of ATPCA (Fig. 4b,d, Supplementary Fig. S3) with the only difference that F293 
shows alternatingly π-cation interactions with N3 and π-face-edge interactions with the ring, and the carboxyl 
Figure 3.  Concentration–response curves for selected ATPCA analogues at hBGT1 stably expressed in 
CHO Flp-In cells in the FMP assay. Data are normalized to the GABA maximum response  (Rmax) and 
are means ± S.E.M. of three independent experiments performed in triplicates. Mean  EC50 values in µM 
 (pEC50 ± S.E.M.): 2, 56 (4.3 ± 0.08); 2, 399 (3.4 ± 0.09); 5, 194 (3.7 ± 0.01) 11, 75 (4.1 ± 0.05); l-15a, 40 (4.4 ± 0.04). 
Mean  Rmax values given as % of GABA  Rmax ± S.E.M.: 2, 103 ± 3.9; 2, 76 ± 2.7; 5, 73 ± 2.8; 11, 95 ± 4.0; l-15a, 
36 ± 2.9. Owing to solubility limitations, a top plateau could not be obtained for 5, and the curve was therefore 
constrained to GABA  Rmax. The fluorescence signals were hBGT1-specific, as no comparable pronounced 
responses were seen at hGAT1 stably expressed in CHO Flp-In cells, when the highest concentrations were 
tested (data not shown). This suggested that the fluorescence responses seen were not due to nonspecific effects, 
such as compound autofluorescence, and that the compounds were truly hBGT1 substrates.
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12992  | https://doi.org/10.1038/s41598-020-69908-w
www.nature.com/scientificreports/
group forms hydrogen bonds with Y132 instead of Y133, which is also conserved among the  GATs37,50,51. This 
binding hypothesis, however, cannot explain the activity difference of ATPCA compared to 11  (IC50 2.5 μM and 
 IC50 48 μM, respectively). Nevertheless, we hypothesize that 11, due to its more rigid scaffold, may adopt ener-
getically less favorable conformations during the transport cycle resulting in a 19-fold lower activity.
The molecular basis for the experimental SAR. The MD-refined docking poses outlined in Fig.  4 
served as a basis for identifying the molecular determinants for subtype-selectivity and for discussing the SAR 
of the remaining compounds of the dataset. Accordingly, 2 contains one nitrogen less in the ring and is therefore 
missing one hydrogen bond donor, thus showing fivefold decreased potency (Table 1). The ethyl group of 3 can 
be accommodated in the pocket, but sterically interferes with the hydrogen bonding of the guanidine moiety and 
the side chains of E52 and Q299, resulting in a 34-fold decreased activity. The exocyclic-N-alkylated 10 shows 
no activity due to steric hindrance by C301 in the lower part of the orthosteric pocket. The 4-alkyl analogs 12, 
Figure 4.  (a) Protein–ligand interactions of ATPCA. The best-scored docking pose was refined by 20 ns 
of molecular dynamics (MD) simulations. The trajectory was clustered according to the ligand, and a 
representative snapshot of the most highly populated cluster was selected as a final binding pose. The molecular 
surface is depicted with hydrophilic areas in blue and lipophilic areas in yellow. (b) Protein ligand interactions 
of 11. The pose was selected according to the same procedure as in (a). (c) Protein–ligand interaction diagram 
of one MD simulation of ATPCA (pink, ionic interactions; green, hydrogen bonding; purple, hydrophobic 
contacts). Two additional replicas gave similar results. An interaction fraction value of 1.0 suggests that during 
the simulation this interaction is maintained 100% of the time. Values greater than 1.0 are possible due to 
multiple contacts of the ligand with the same residue. (d) Protein–ligand interaction diagram of 11. Two 
additional replicas gave similar results.
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13, and 14 interfere with F293 and are sterically too demanding to fit into the small pocket. The same steric hin-
drance is observed for 16–19, which share the same flexible scaffold as ATPCA, but also contain bulky substitu-
ents in position 4. For l-15a,b and u-15a,b, the same binding mode as for ATPCA is predicted. Unfortunately, 
the absolute configuration at the stereocenters bearing the carboxyl and the methyl group is unknown, which 
precludes a detailed interpretation of the activity differences observed. We assume that compared to 12, the 
missing double bond may allow more flexibility in positioning the methyl group enabling a better fit of l-15a,b 
and u-15a,b into the pocket. Moreover, the l and u enantiomeric pairs show stereoselective activity, where the 
l-15a,b and the u-15a,b enantiomers differ by 13 and 3 times, respectively. These activity differences underline 
the limited space that is available in this part of the pocket.
For the BGT1-active 4 and 5, we postulate a slightly different binding hypothesis, since the N1-benzyl and 
biphenyl substituents are too bulky to fit into the orthosteric pocket of the occluded transporter model. This is 
supported by the observation that within the most populated cluster, no poses of 4 and 5 are present. Accord-
ingly, 4 and 5 can only be accommodated in the extracellular vestibule of the transporter which is facilitated by 
the opening of the extracellular gate (residues T133, F293, R61 and D452)37. This is quite remarkable because 
we demonstrated that 5 is still transported which would require the closure of the external gate according to the 
classical alternating-access transport  model55,56. According to the docking results, in order to accommodate the 
bulky substituents in the extracellular vestibule while the carboxyl moiety of 4 and 5 coordinates the sodium ion 
in the orthosteric pocket, which is considered to be the most plausible  placement37,57, the carboxyl group needs 
to shift from an equatorial to an axial conformation allowing the compounds to bend. To further probe this 
notion and to refine the docking poses of 4 and 5 we simulated the top Emodel scored poses of each compound 
for 20 ns at least three times (Fig. 5 and Supplementary Fig. S4). All simulations showed that the accommoda-
tion of the bulky substituents towards the extracellular vestibule resulted in greater distances particularly in the 
lipophilic extracellular gate (Y133 and F293) compared to the ATPCA wt simulations (Supplementary Fig. S5). 
The carboxyl group of 4 adopted an axial conformation in three out of four simulations, whereas the carboxyl 
group of 5 adopted an axial conformation in all three simulations, confirming that conformational flexibility 
is important for accommodating increasing bulk while maintaining the coordination of the sodium ion (Sup-
plementary Fig. S6). Similarly to ATPCA, the carboxyl group of 4 showed additional interactions with G57 and 
Y133, whereas the carboxyl group of 5 only interacted with G57. In contrast to ATPCA, the guanidine group of 
4 solely forms hydrogen bonds with the backbone of F293 and only shows long term-interaction with E52 in the 
single simulation where the carboxyl group adopts an equatorial conformation (Supplementary Fig. S4). The 
guanidine group of 5, however, did show hydrogen bonding with the BGT1 specific residues Q299 and E52 as 
well as with Y133 in all simulations which could explain why 5 is more potent and more selective than 4 (Supple-
mentary Fig. S4). We hypothesize that the increased bulk of 5 stabilizes the plane of the ATPCA scaffold in a more 
favorable angle to undergo interactions with Q299 and E52 compared to 4. According to this binding hypothesis, 
6 and 7 are sterically too demanding to fit into the extracellular vestibule and therefore do not show activity.
Validation of the proposed molecular interaction pattern by mutational experiments. Over-
all, the docking studies and MD simulations showed that the residues Q299 and E52 in hBGT1 can undergo 
key interactions with the guanidine moiety of ATPCA and its analogs. As Q299 and E52 are not conserved 
among the GATs, we further propose these residues as molecular determinants for the hBGT1-selectivity of 
these compounds. To evaluate the importance of these residues for activity and selectivity, mutagenesis experi-
ments were performed, and 2, 3, 4, 11, and l-15a were evaluated in  [3H]GABA uptake assays. Therefore, Q299 
and E52 in hBGT1 were mutated to either alanine or the corresponding residues in the other hGAT subtypes 
(hBGT1 Q299L, E52A, E52Y, E52A + Q299L, and E52Y + Q299L). According to our binding hypothesis, 2, 3, 11, 
and l-15a were predicted to show decreased activity at any of the mutants, whereas no change in activity was 
expected for 4 due to the adoption of a slightly different binding mode where Q299 and E52 are not relevant. In 
contrast, glutamine was introduced in the corresponding position L314Q in GAT3 and predicted to introduce 
activity for 2, 3, 11, and l-15a, but not for 4.
Table 2 summarizes the effects of the mutations in hBGT1 and hGAT3 on the potencies of GABA, ATPCA, 
2, 3, 4, 11, and l-15a. The hBGT1 E52Y + Q299L double mutant was proven not functional, as evident from the 
lack of  [3H]GABA uptake (data not shown), while the other hBGT/hGAT3 mutants were functional, albeit with 
a lower total uptake compared to their wildtype (wt) counterparts (cf. CPM values in the caption of Table 2, for 
more details on the cell surface expression of the mutants see Supplementary Fig. S7). Furthermore, we consist-
ently noticed a small decrease in the inhibitory potency of the tested compounds using transient GAT expression 
in tsA201 cells (Table 2) versus stable expression in CHO cells (Table 1)36. Generally, the inhibitory activity of 
GABA was increased at all hBGT1 mutants except for E52A which comprises the only “unnatural” mutation 
not related to any of the neurotransmitter transporters. This supports the notion that by making hBGT1 more 
similar to hGAT1, GABA activity will be increased due to naturally higher GABA activity at hGAT 58. Interest-
ingly, ATPCA and 3 did not show the predicted decrease of inhibitory activity at any of the single-point hBGT1 
mutants, i.e. Q299L, E52Y, and E52A, compared to wt hBGT1, whereas 2 only showed decreased activity at 
the Q299L mutant. Yet, the activity of ATPCA and 3 were both decreased at the double mutant E52A + Q299L 
(see Table 2). On the other hand, the activities of 11 and l-15a could be decreased at the single-mutants hBGT1 
Q299L and E52Y, and at the double mutant E52A + Q299L. Noteworthy, a trend for increased inhibitory activ-
ity was observed for the E52A mutant over all compounds except for compound 11. Introducing the hBGT1-
specific Q299 in the corresponding hGAT3 position,  L314Q44,50, allowed the introduction of activity for ATPCA 
and to some extent for 2, which strongly supports the notion that Q299 is relevant for activity and selectivity. 
Intriguingly, the same mutant failed to restore the activity of 3, 11, and l-15a. The analysis of the  [3H]GABA 
uptake assay results of 4 showed that the activity was increased at all single hBGT1 mutants, but unaltered at the 
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hBGT1 double mutant. This is in agreement with our simulations of 4 where its carboxyl group adopts an axial 
conformation and no long-term interactions with Q299 and E52 are formed, which renders these residues not 
relevant for binding. Accordingly, 4 also displayed decreased activity at the GAT3 L314Q mutant compared to 
wt hGAT3 underlining once more a different binding mode not involving Q299L.
Most interestingly, our model showed notable inconsistencies regarding the predicted activities of ATPCA, 2 
and 3 versus 11 and l-15a at the mutants. While 11 and l-15a display the predicted loss in inhibitory activity at the 
hBGT1 mutants (except for E52A), we failed to restore activity in the hGAT3 Q314 mutant. In contrast, ATPCA 
and 3 only showed decreased activity at the hBGT1 double mutant, whereas 2 showed only decreased activity at 
the hBGT1 Q299L mutant. Yet, for ATPCA and 2 we successfully restore activity at the hGAT3 mutant, L314Q. 
In view of the structural resemblance of ATPCA and 11 and their similar molecular interactions predicted by 
the MD-refined docking poses (Fig. 4), we consider these different inhibition profiles particularly striking. We 
Figure 5.  (a) Protein–ligand interactions of 4. The best-scored docking pose was refined by 20 ns of molecular 
dynamics (MD) simulations. The trajectory was clustered according to the ligand, and a representative 
snapshot of the most highly populated cluster was selected as a final binding pose. The molecular surface is 
depicted with hydrophilic areas in blue and lipophilic areas in yellow. (b) Protein–ligand interactions of 5. The 
pose was selected according to the same procedure as in (a). (c) Protein–ligand interaction diagram of one 
MD simulation of 4 (pink, ionic interactions; green, hydrogen bonding; purple, hydrophobic contacts; blue, 
water contacts). Two additional replicas gave similar results. An interaction fraction value of 1.0 suggests that 
during the simulation this interaction is maintained 100% of the time. Values greater than 1.0 are possible 
due to multiple contacts of the ligand with the same residue. (d) Protein–ligand interaction diagram of 5. Two 
additional replicas gave similar results.
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therefore conclude that GAT activity and selectivity is more complex than the potential interaction with E52 and 
Q299 and that flexibility, constituting the only structural difference between ATPCA and 11, could account for 
the observed different inhibition profiles. Compared to ATPCA, 11 contains an additional double bond between 
C4 and C5 (Fig. 1), which renders the structure more rigid. Hence, the seemingly flexible molecules of ATPCA, 2, 
and 3 could have adopted new conformations, such as the equatorial to axial shift of the carboxyl group already 
observed for 4 and 5, which possibly allows to compensate to some extent the loss of interactions at the hBGT1 
mutants. Analogously, the highly flexible GABA molecule has been suggested to adopt an extended or a “cyclic” 
conformation in the pocket of  GATs59. Accordingly, the same flexibility could also account for reintroducing 
activity of ATPCA and 2 at the hGAT3 mutant L314Q, whereas 3, 11 and l-15a remained inactive. l-15a displays 
a similar inhibitory profile compared to 11 at the mutants even though l-15a is lacking the additional double 
bond in the common scaffold. We hypothesize that l-15a is less flexible in the pocket due to the 4-methyl moiety 
that shows a stereospecific activity profile probably due to steric hindrance (Table 2). Nevertheless, we also need 
to address the possibility that our homology model is inaccurate, which is a general concern for any model built 
on a template with low sequence identity. However, previous mutational studies at hBGT1 have demonstrated 
that hBGT1 is remarkably resistant to  mutations60. Consequently, we consider the presented mutational data as 
rather successfully in light of the challenging target.
To examine the postulated link between the conformational flexibility of the compounds and the activity 
observed at the mutants, we performed MD simulations of ATPCA, 4 and 11 at the hBGT1 mutants (Supplemen-
tary Figs. S8–S19). The best-scored poses of each of the three compounds were mutated in silico and simulated 
for 20  ns61,62. The trajectories were hierarchically clustered according to the ligand, and the interaction patterns 
were analyzed. Although no additional compensatory interactions were observed for ATPCA, we noted that 
ATPCA’s carboxyl group shifted from an exclusively equatorial conformation in wt hBGT1 to adopt also axial 
conformations in all hBGT1 mutants (Fig. 6a–f). These conformations are similar to the conformations that allow 
4 and 5 to accommodate their bulky substituents in the extracellular vestibule. Furthermore, we observed that 
the carboxyl group of 4 also adopted this axial conformation throughout all simulations of the mutants (Sup-
plementary Fig. S6). Conversely, MD simulations of 11 showed a flat structure in all hBGT1 mutants similar to 
the wt transporter (Supplementary Fig. S20). The MD simulations therefore support the notion that ATPCA can 
potentially adopt additional conformations in the hBGT1 mutants, similarly to 4, which might be implicated in 
the observed compensatory mechanism in the hBGT1 mutants.
To further support this notion, we synthesized two analogs of 4, where 9 contains an additional double 
bond in the scaffold between C5 and C6 and 8 contains a 4,4-bis(3-methyl-2-thienyl)3-butenyl substituent at 
N1 which corresponds to the substituents of the dual GAT1/BGT1 inhibitor  EF150229 (Figs. 1, 2a). According to 
our hypothesis, we predicted 9 to be inactive at wt hBGT1 due to the rigid scaffold which renders the compound 
incapable to adopt the axial conformation of the carboxyl group which our simulations and the mutational data 
suggested to be the most plausible binding conformation. In contrast, we predicted compound 8 to show at 
Table 2.  Effect of mutations in hBGT1 and hGAT3 on the inhibitory activities of GABA, ATPCA, and 
selected analogs. The compounds were examined for their ability to inhibit the uptake of 30 nM  [3H]GABA at 
wildtype (wt) hBGT1 or hGAT3, or at mutated transporters transiently expressed in tsA201 cells. At least three 
independent experiments in triplicates were performed. Total and non-specific  [3H]GABA uptake gave the 
following approximate CPM values, respectively: 4,000 and 60 (hBGT1 wt); 700 and 55 (Q299L); 600 and 60 
(E52Y); 7,500 and 120 (E52A); 450 and 50 (E52A + Q299L); 8,500 and 70 (hGAT3 wt), 3,500 and 75 (L314Q). 
The  pIC50 values at the mutants were compared to the wt transporter (unpaired Student’s t-test, not significant 
(ns), P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Lowered  [3H]GABA uptake by the mutants 
hBGT1 Q299L, E52A + Q299L, and E52Y + Q299L was correlated with lower cell surface expression levels 
determined by ELISA (see Figure S7). E52A and E52Y showed similar surface expression levels as hBGT1 
which suggests that the observed decreased  [3H]GABA uptake is a result of impaired transport properties. 
Concentration response curves for all compounds can be found in the Supplementary Fig. S23.
IC50  (pIC50 ± S.E.M.) (µM)
BGT1 GAT3
wt Q299L E52Y E52A E52A + Q299L wt L314Q
GABA 18(4.74 ± 0.03)
1.4
(5.87 ± 0.02)****
1.2
(5.92 ± 0.05)****
25
(4.60 ± 0.03)ns
1.0
(6.01 ± 0.08)****
8.2
(5.10 ± 0.02)
5.2
(5.29 ± 0.04)*
ATPCA 11(4.98 ± 0.06)
13
(5.89 ± 0.10)ns
5.8
(5.24 ± 0.06)ns
4.4
(5.36 ± 0.04)**
36
(4.52 ± 0.15)*
851
(3.23 ± 0.14)
66
(4.23 ± 0.10)***
2 52(4.29 ± 0.03)
108
(3.98 ± 0.07)*
44
(4.43 ± 0.13)ns
31
(4.52 ± 0.02)**
133
(3.96 ± 0.14)ns  > 1,000
695
(3.16 ± 0.11)
3 406(3.40 ± 0.05)
203
(3.72 ± 0.10)ns
152
(3.82 ± 0.05)**
74
(4.14 ± 0.05)***  > 1,000  > 1,000  > 1,000
4 354(3.49 ± 0.09)
157
(3.85 ± 0.09)*
54
(4.27 ± 0.07)***
90
(4.06 ± 0.07**)
317
(3.60 ± 0.10)ns
122
(3.94 ± 0.10)
500
(3.31 ± 0.05)**
11 220(3.66 ± 0.05)  > 1,000  > 1,000
247
(3.62 ± 0.06)ns  > 1,000  > 1,000  > 1,000
l-15a 21(4.68 ± 0.02)  > 1,000  > 1,000
37
(4.43 ± 0.02)***  > 1,000  > 1,000  > 1,000
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least some activity due to the flexible scaffold that allows the accommodation of the bulky N3-substituent in the 
extracellular vestibule. The two compounds were evaluated in  [3H]GABA uptake assays at hBGT1 transiently 
expressed in tsA201 cells. Three independent experiments performed in triplicates confirmed that 9 showed no 
activity at hBGT1 wt  (IC50 > 1,000 µM), whereas 8 showed some activity  (IC50 621uM,  pIC50 3.2 ± 0.03) (Table 1). 
These findings support our hypothesis that flexibility plays a crucial role for adopting the alternative binding 
hypothesis of 4 and 5 that allows the accommodation of bulky substituents as well as it potentially lays the ground 
for compensating the missing interactions for ATPCA, 2 and 3 at the mutants.
conclusion
Overall, our proposed binding mode can explain the SAR of all presented compounds in this study. Furthermore, 
our findings suggest that hBGT1 subtype selectivity of ATPCA and its analogs is complex as it is potentially 
governed not only by hydrogen bonding between the guanidine moiety and the residues E52 and Q299, but also 
by the flexibility of the compounds itself. Finally, our computational and experimental results suggest that the 
bulky compounds 4 and 5 adopt a slightly different binding mode than ATPCA and its small analogs, which 
possibly explains their decreased subtype selectivity. This binding mode can only be adopted due to a shift from 
the equatorial to an axial conformation of the carboxyl group of 4 and 5, which allows the bulky N1 substituents 
to extend into the extracellular vestibule of hBGT1. Since this binding mode requires the opening of the external 
gate, it remains elusive how these compounds can be still transported. Similar conformational flexibility was 
also observed for ATPCA in MD simulations of the hBGT1 mutants Q299L, E52A, E52Y and E52A + Q299L. 
We therefore believe that this flexibility can to some extent compensate for the missing interactions of ATPCA, 
2 and 3 in the hBGT1 mutants. Further confirmation was obtained by compound 9, a rigid analog of 4, which 
showed no activity at hBGT1. Overall, our experimentally validated binding hypothesis of a series of BGT1-
selective substrate-inhibitors contributes to the understanding of GAT subtype selectivity and herein forms a 
versatile basis to guide the rational design of more potent BGT1 inhibitors.
experimental section
Materials and compounds. Hank’s Balanced Salt Solution (HBSS, no calcium, no magnesium no phe-
nol red), Dulbecco’s Phosphate Buffered Saline (DPBS), Ham’s F12 Nutrient Mix, Dulbecco’s Modified Eagle 
Medium (DMEM) containing GlutaMAX-I, fetal bovine serum (FBS), penicillin–streptomycin (P/S), hygromy-
cin B, and trypsin were purchased from Life Technologies (Paisley, UK). Plasmocin was purchased from Invi-
voGen (San Diego, CA, USA). PolyFect Transfection Reagent was purchased from Qiagen (West Sussex, UK). 
GABA, poly-d-lysine (PDL), and HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).[2,3-3H(N)]GABA (35.0 Ci/mmol).
Plasmids. Epitope tagging of hBGT1 and hGAT3, subcloned into the pcDNA5/FRT  vector58, with an 
extracellularly located human influenza hemagglutinin (HA) peptide tag (YPYDVPDYA) has been previously 
 described60. The mutated constructs, hBGT1 E52Y, E52A, C301S, Q299L + E52A, and Q299L + E52Y were syn-
thetized by Genscript (Piscataway, NJ, USA), while the generation of the hBGT1 Q299L and hGAT3 L314Q 
mutants has been previously  described60.
Figure 6.  (a) Illustration of the measured dihedral angle between the carboxyl group and the 
tetrahydropyrimidine ring of ATPCA. (d–f) Density distributions of dihedral angles between the carboxyl group 
and the tetrahydropyrimidine ring of ATPCA in simulations of ATPCA in the wt hbGT1 and all mutants (bin 
width corresponds to ten degrees). Every tenth snapshot of every trajectory including all replicas were extracted 
(in total 1,251 snapshots per mutant) and the dihedral angles were calculated with  vmd70. In contrast to ATPCA 
in wt hBGT1, the carboxyl group can adopt equatorial conformations (dihedral angle of ~ 90°) in all mutants.
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:12992  | https://doi.org/10.1038/s41598-020-69908-w
www.nature.com/scientificreports/
Pharmacology. Cell culture and transfection. CHO Flp-In and tsA201 cells were cultured at 37 °C in a hu-
midified atmosphere of 95%  O2 and 5%  CO2. As previously  described38,63, CHO Flp-In cells stably expressing the 
hGATs were cultured in Ham’s F12 Nutrient Mix supplemented with 10% FBS, 1% P/S and plasmocin (5 µg/mL) 
under the selection pressure of hygromycin B (200 µg/mL). DMEM with GlutaMAX-I supplemented with 10% 
FBS and 1% P/S was used as growth medium for the tsA201 cells, which were transfected with DNA constructs 
using PolyFect according to the manufacturer’s specifications (Qiagen, West Sussex, UK), but with half of the 
recommended reagent volumes.
Radioligand-based uptake assays. Uptake assays were performed in PDL-coated white 96-well polystyrene cell 
culture microplates (PerkinElmer, Boston, MA, USA) as previously  described38,63. Approximately 16–20 h after 
cell plating (~ 50.000 cells/well), cells were incubated with 30 nM of  [3H]GABA with and without varying con-
centrations of ligands for 3 min at 37 °C. Assay buffer was HBSS supplemented with 20 mM HEPES, 1 mM  CaCl2 
and 1 mM  MgCl2, pH 7.4. Non-specific  [3H]GABA uptake was determined in the presence of 3 mM GABA. 
After termination, scintillation liquid (MicroScint-20, PerkinElmer) was added and the radioactivity measured 
in a TopCount NXT Microplate Scintillation Counter (PerkinElmer).
The FLIPR Membrane Potential (FMP) assay. The fluorescence-based FMP assay was performed as previously 
 described64, for the functional characterization of the electrogenic transport of substrates via hBGT1. Briefly, 
CHO Flp-In cells stably expressing hBGT1 or hGAT1 were plated (~ 50,000 cells/well) into black PDL-coated 
96-well plates with clear bottom (VWR, Radnor, PA, USA). The next day, the growth medium was removed, and 
cells were washed once with HBSS assay buffer and FMP Blue Dye (Molecular Devices, Crawley, UK), added, 
and incubated. Ligands were added via the NOVOStar plate reader (BMG Labtech GmbH, Offenburg, Ger-
many), preheated to 37 °C, approximately 10 min before reading of the cell plate. The fluorescence signals were 
measured for 33.8 s upon ligand addition using an emission and excitation wavelength of 560 nm and 530 nm, 
respectively. Electrogenic transport of substrates via hBGT1 will lead to an influx of the negatively charged FMP 
Blue dye that will bind to intracellular proteins and lipids resulting in an increase in the fluorescence signal.
Enzyme-linked immunosorbent assay (ELISA). ELISA was performed exactly as previously described using 
tsA201 cells transiently expressing HA-tagged or untagged hBGT1  constructs65. To this end, washed, fixated, 
blocked cells were incubated for 45 min with anti-HA (anti-HA.11, BioLegend, San Diego, CA, USA) diluted 
1:1,000 in blocking solution, washed carefully and incubated for 45 min with a horseradish peroxidase-conju-
gated antibody (anti-mouse, P0447, Dako, Glostrup, Denmark) diluted 1:1,500 in blocking solution. Finally, 
quantification of the signal from well-washed cells were obtained using SuperSignal ELISA Femto substrate 
(ThermoFisher Scientific, Waltham, MA USA) by chemiluminescence in an EnSpire2300 Multilabel Reader 
(PerkinElmer). HA-tagged hBGT1 was used as a positive control, while untagged wt hBGT1 was used as a nega-
tive control. All experiments were performed in sextuplicate measurements in three independent experiments.
Data analysis. Data analysis and statistical evaluation were performed in GraphPad Prism 7.02 (GraphPad 
Software, San Diego, CA, USA). Concentration-uptake inhibition curves, generated from the radioligand-based 
uptake assays, were fitted by non-linear regression, using the equation for sigmoidal concentration–response 
with variable slope: Y = Bottom + (Top–Bottom)/(1 + 10^((logIC50 − X) × HillSlope)), where Y is the response, 
X is the logarithm of the concentration, Top and Bottom are the plateaus in same units as Y,  logIC50 is the con-
centration giving a response halfway between Bottom and Top, and the HillSlope is the steepness of the curve. 
For the substrate concentration–response curves generated from the FMP assay, the same equation was used but 
with  logEC50 instead for  logIC50. Unpaired Student’s t-test was performed when appropriate, as indicated in the 
figure legends. Unless otherwise stated, data are presented as means ± S.E.M. of at least three independent pooled 
experiments performed in triplicates.
Modeling. Model building. Homology models of hBGT1 in the outward-occluded state were (template: 
PDB code 2A65)51 used from the publication of Damgaard et al.44.
Docking. Induced fit docking was performed with the Schrödinger Suite 2015-2 using the OPLS2005 force field 
and extended  sampling45. Ligands were drawn in ChemDraw 15.0.0.106, and ligand preparation was carried 
out with  LigPrep66 using pH 7.4 ± 1. Protein preparation was done with  PrepWiz67. Compounds with unknown 
absolute configuration of the carboxyl group (2–5, 11–14, l-15a,b, and u-15a,b) were docked in R and S configu-
rations. ATPCA shows a delocalized double bond within the guanidine moiety, thus, there is no stereo center 
at the carboxyl group. Due to the protonation of N3, the Schrödinger Suite automatically assigns different atom 
types to N1 and  N3 which forces the user to define the stereocenter at C1. Since the OPLS2005 force field does not 
provide a suitable standard atom type that unites the characteristics of N1 and  N3, we decided to dock ATPCA in 
an R and S configuration. 752 docking poses were generated and visualized with MOE 2016.0868. A hierarchical 
clustering of the poses was performed according to an in-house protocol for common scaffold clustering with 
a maximal distance of 3 Å within one  cluster48. The poses were assembled into 33 clusters and the most popu-
lated cluster was considered as most promising. Within the cluster, poses with the highest Emodel  score49 were 
selected for further MD refinement.
Molecular dynamics. MD simulations were performed with Desmond 4.261,62 for 20 ns at least three times for 
each pose, using OPLS2005 force field, SPC solvent model, POPC (300 K) as a membrane model and 0.15 M NaCl 
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salt concentration. The system was placed in a box with periodic boundary conditions and relaxed according 
to the standard protocol (NVT ensemble with short time steps with Brownian dynamics at 10 K and restrained 
solute heavy atoms, NVT ensemble using Berendsen thermostat, NPT ensemble using Berendsen thermostat 
and barostat). The production run was performed according to the standard protocol (NPT ensemble at 300 K, 
Berendsen thermostat and barostat, recording intervals of 1.2 ps for the energy and 4.8 ps for the trajectory). 
The trajectory was hierarchically clustered into 10 clusters according to the ligand with the python script trajec-
tory_clustering.py available in the Schrödinger suite 2015-269. For ATPCA, we simulated both the top-scored R 
and S configured poses (including one replica) to confirm that we observe the same interactions (see Fig. 4 and 
Fig. S3, data not shown for the S configuration).
Chemistry. All synthetic procedures can be found in the Supplementary information page 25.
Data availability
The datasets generated and analysed during this study (the homology model, docking poses, simulation tra-
jectories and code for analyzing the trajectories as well as code for generating figures) are available from the 
corresponding author upon request.
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